LEE SPENCER S sold $494K of CHE

LEE SPENCER S (executive vice president) sold 920 shares of CHEMED CORP (CHE) at $537.17 ($0.49M total) on 2026-11-02.

Original reporting
SEC EDGAR · LEE SPENCER S
Published Nov 3, 2026, 6:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 6:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CHE
Neutral
medium confidence
Mentioned
$CHE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CHENeutralLow
01

Why it matters

This provides incremental sentiment information via an EVP’s sale, but it does not include any new company fundamentals, guidance, or corporate action.

02

Market read

Traders may briefly note insider selling, but the event is unlikely to materially change valuation without additional fundamental news.

03

What to watch

No 10b5-1 plan is indicated, but absence of a plan does not prove negative fundamentals; insider sales are common around taxes, planned expenses, or scheduled personal liquidity needs.

Relevance 4/10Novelty 4/10Timing: filed 2026-11-03, transaction dated 2026-11-02

Background

The article is a SEC Form 4 insider transaction disclosure for Chemed Corp (CHE).

Company-level read

Ticker impact

$CHENeutralMedium confidence
Context

Chemed Corp is the Form 4 issuer, showing EVP Lee Spencer S sold 920 shares at $537.17 on 2026-11-02 for about $494K.

Expected impact

Likely limited near-term impact, with any move driven more by broader tape than the insider sale itself.

Evidence & confidence

The filing is a routine insider transaction (S code) with no 10b5-1 plan stated, but the disclosed size is modest and there is no accompanying operational or guidance catalyst.

Market effects

Minimal, as this is a single-company insider sale with no sector-wide signal.

None.

None.

Counterpoint

The sale may be purely liquidity or diversification-driven, especially since it is an open-market transaction and the holdings remain substantial.

Key entities

  • CHEMED CORP

    Chemed Corp, the Form 4 issuer for the insider sale.

  • LEE SPENCER S

    Executive Vice President who sold 920 shares on 2026-11-02.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CHEMedAI 9/10

Chemed 3Q 2026: Revenue $690.9M, EPS $5.45— 10-Q Summary

Chemed reported Q3 2026 revenue of $690.9M, up 10.6% YoY, with net income rising 11.5% to $71.6M and EPS increasing 22.2% to $5.45. Growth in VITAS and Roto-Rooter segments drove results, while higher fuel costs pressured margins. The company acquired RotoCo and other franchises, expanding its territories.

$CHEMed

What Chemed (CHE) Said on Its Q3 Earnings Call

Chemed reported Q3 earnings, with Roto-Rooter revenue up 7.5% but EBITDA down 2.5% due to higher costs. Commercial revenue grew 9% to $59.9M, while residential rose 5.2% to $158.8M. The company acquired California franchises for $62.5M, expecting $30M-$35M in 2027 revenue but less than $4M in EBITDA. Chemed repurchased 125,000 shares for $66M. Management expects 2026 EPS to meet or slightly exceed guidance.

$CHEMed

Chemed outlines 12- to 18-month integration timeline for $62.5M California Roto-Rooter franchise buyback while expecting 2026 EPS at or slightly above prior high end (NYSE:CHE)

Chemed (CHE) announced a 12- to 18-month integration timeline for its $62.5M California Roto-Rooter franchise buyback. CEO Kevin McNamara reported VITAS revenue grew 12.2% year-over-year, driven by ADC growth and cost containment. The company expects 2026 EPS to be at or slightly above the prior high end.

$CHEHighAI 8/10

Chemed (CHE) Q3 2026 Earnings Call Transcript

Chemed (CHE) reported Q3 2026 earnings with total revenue up 10.6% and adjusted EPS up 28.1% YoY. VITAS saw 12.2% revenue growth, while Roto Rooter grew 7.5%. Roto Rooter's margins declined due to higher marketing costs and fuel expenses, but acquisitions are expected to drive long-term growth. The company has $229M in cash flow from operations, enabling strategic acquisitions and share repurchases.

$CHEHighAI 8/10

Why is Chemed stock surging today?

Chemed (CHE) stock rose 9.2% after Q3 earnings beat estimates, with adjusted EPS of $6.75 and revenue of $690.9M. VITAS hospice division showed strong growth. Jefferies upgraded the stock to Buy, raising its price target to $620. Bank of America also increased its target to $555. The stock hit a 52-week high.